About this trial
To evaluate the pathological complete response rate (pCR) of nivolumab combined with SOX (oxaliplatin + S-1) for neoadjuvant therapy of resectable gastric and gastroesophageal junction adenocarcinoma;
Eligibility criteria
Qualifiers
None
Disqualifiers
Patients with unresectable factors, including unresectable tumor causes or unresectable surgical contraindications or refusal of surgery;
Previous or concurrent other malignancy;
Suffering from any chronic or major illness considered intolerable to treatment (eg, severe cardiac disease, uncontrolled hypertension, some degree of hepatic or renal dysfunction, etc.)
Patients who have previous gastrointestinal perforation, abdominal abscess or recent (within 3 months) intestinal obstruction or imaging and clinical symptoms suggestive of intestinal obstruction;
Trial design
Treatments tested in this trial
- nivolumab combined with SOX
Treatment groups
Sponsors and collaborators
Xiangdong Cheng
Lead sponsor
Zhejiang Cancer Hospital
Sponsor institution